Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0001148
Title: Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial
Authors: Pan A. 
Sun J.
Chen Y.
Ye X.
Li H.
Yu Z.
Wang Y.
Gu W.
Zhang X.
Chen X.
Wendy D.-W.
Liu Y.
Lin X.
Keywords: enterodiol
enterolactone
flax essence
glucose
hemoglobin A1c
insulin
isoflavone derivative
lignan
lipid
placebo
lignan
adult
aged
article
China
clinical trial
controlled clinical trial
controlled study
crossover procedure
diarrhea
double blind procedure
drug bioavailability
drug efficacy
drug excretion
female
flatulence
glycemic control
human
hypercholesterolemia
insulin resistance
insulin sensitivity
linseed
lipid blood level
major clinical study
male
nausea
non insulin dependent diabetes mellitus
randomized controlled trial
treatment duration
chemistry
diet therapy
flax
middle aged
non insulin dependent diabetes mellitus
treatment outcome
Animalia
Aged
Cross-Over Studies
Diabetes Mellitus, Type 2
Double-Blind Method
Female
Flax
Humans
Lignans
Male
Middle Aged
Placebos
Treatment Outcome
Issue Date: 2007
Citation: Pan A., Sun J., Chen Y., Ye X., Li H., Yu Z., Wang Y., Gu W., Zhang X., Chen X., Wendy D.-W., Liu Y., Lin X. (2007). Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial. PLoS ONE 2 (11) : e1148. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0001148
Rights: Attribution 4.0 International
Abstract: Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal Findings. This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10�65 % vs. 0.09�52 %, P=0.001) compared to placebo; however no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2�.1 vs. 1.2=2.4 ?g/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. Conclusions/Significance. Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes. � 2007 Pan et al.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/161861
ISSN: 19326203
DOI: 10.1371/journal.pone.0001148
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0001148.pdf283 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons